Orexo Future Growth
Future criteria checks 4/6
Orexo is forecast to grow earnings and revenue by 71.8% and 11.3% per annum respectively while EPS is expected to grow by 71.8% per annum.
Key information
71.8%
Earnings growth rate
71.8%
EPS growth rate
Pharmaceuticals earnings growth | 23.8% |
Revenue growth rate | 11.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 25 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 686 | -20 | 58 | 63 | 1 |
12/31/2025 | 583 | -79 | -4 | N/A | 1 |
12/31/2024 | 584 | -120 | -37 | -32 | 1 |
9/30/2024 | 596 | -105 | -46 | -41 | N/A |
6/30/2024 | 615 | -97 | -61 | -50 | N/A |
3/31/2024 | 619 | -73 | -72 | -52 | N/A |
12/31/2023 | 639 | -128 | -114 | -95 | N/A |
9/30/2023 | 629 | -201 | -172 | -141 | N/A |
6/30/2023 | 634 | -195 | -205 | -180 | N/A |
3/31/2023 | 624 | -218 | -176 | -157 | N/A |
12/31/2022 | 624 | -178 | -180 | -157 | N/A |
9/30/2022 | 612 | -152 | -203 | -188 | N/A |
6/30/2022 | 597 | -177 | -241 | -207 | N/A |
3/31/2022 | 592 | -216 | -285 | -243 | N/A |
12/31/2021 | 565 | -223 | -282 | -229 | N/A |
9/30/2021 | 580 | -207 | -239 | -160 | N/A |
6/30/2021 | 585 | -240 | -201 | -93 | N/A |
3/31/2021 | 621 | -198 | -281 | -79 | N/A |
12/31/2020 | 664 | -84 | -173 | 17 | N/A |
9/30/2020 | 743 | 4 | -94 | 84 | N/A |
6/30/2020 | 824 | 201 | 89 | 231 | N/A |
3/31/2020 | 846 | 288 | 248 | 284 | N/A |
12/31/2019 | 845 | 219 | 255 | 287 | N/A |
9/30/2019 | 834 | 232 | 286 | 302 | N/A |
6/30/2019 | 819 | 182 | 192 | 194 | N/A |
3/31/2019 | 818 | 178 | 183 | 187 | N/A |
12/31/2018 | 783 | 138 | 238 | 242 | N/A |
9/30/2018 | 747 | 113 | 144 | 147 | N/A |
6/30/2018 | 697 | 79 | N/A | 215 | N/A |
3/31/2018 | 656 | 32 | N/A | 225 | N/A |
12/31/2017 | 644 | 23 | N/A | 147 | N/A |
9/30/2017 | 637 | 19 | N/A | 241 | N/A |
6/30/2017 | 653 | 27 | N/A | 191 | N/A |
3/31/2017 | 682 | 29 | N/A | 151 | N/A |
12/31/2016 | 706 | 29 | N/A | 156 | N/A |
9/30/2016 | 752 | -57 | N/A | 84 | N/A |
6/30/2016 | 710 | -139 | N/A | -38 | N/A |
3/31/2016 | 648 | -229 | N/A | -82 | N/A |
12/31/2015 | 646 | -210 | N/A | -109 | N/A |
9/30/2015 | 636 | -95 | N/A | -116 | N/A |
6/30/2015 | 627 | -85 | N/A | -188 | N/A |
3/31/2015 | 617 | -51 | N/A | -381 | N/A |
12/31/2014 | 570 | -57 | N/A | -487 | N/A |
9/30/2014 | 449 | -146 | N/A | -593 | N/A |
6/30/2014 | 440 | -138 | N/A | -671 | N/A |
3/31/2014 | 391 | -204 | N/A | -358 | N/A |
12/31/2013 | 429 | -155 | N/A | -263 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORXO.Y is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: ORXO.Y is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ORXO.Y is expected to become profitable in the next 3 years.
Revenue vs Market: ORXO.Y's revenue (11.3% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: ORXO.Y's revenue (11.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ORXO.Y's Return on Equity is forecast to be high in 3 years time